On Nov 19, major Wall Street analysts update their ratings for $Twist Bioscience (TWST.US)$, with price targets ranging from $35 to $58.
J.P. Morgan analyst Rachel Vatnsdal maintains with a sell rating, and maintains the target price at $35.
Barclays analyst Luke Sergott maintains with a buy rating, and maintains the target price at $52.
TD Cowen analyst Brendan Smith maintains with a buy rating, and maintains the target price at $58.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and adjusts the target price from $46 to $48.
Furthermore, according to the comprehensive report, the opinions of $Twist Bioscience (TWST.US)$'s main analysts recently are as follows:
Twist Bioscience had a strong recent quarter and appears set to meet its projections of 50% gross margins by Q4. This performance comes amidst a challenging budgetary environment, yet the company's outlook for fiscal 2025 remains promising.
Twist Bioscience showed broad-based solid performance, with each segment modestly surpassing revenue expectations as compared to guidance. The sustained momentum in synthetic biology and next-generation sequencing, along with discussions related to the Express portfolio, and general margin percentage improvements, foster a constructive outlook heading into FY25.
Here are the latest investment ratings and price targets for $Twist Bioscience (TWST.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.